cholecalciferol and Diarrhea

Some studies have reported the possible role of vitamin D. We searched the PubMed and Google Scholar electronic databases for relevant articles without limiting their year of publication. We selected primary studies that met the review's inclusion criteria, screened their titles and abstracts, and removed duplicates. We extracted data items from selected studies using a structured data-extraction form. We conducted a quality assessment of randomized controlled trials (RCTs) and non-randomized studies with the Cochrane collaboration tool and the Newcastle Ottawa Scale, respectively. We assessed the strength of the relationship between serum vitamin D levels and diarrhea using the correlation model. We estimated the I. Nine full-text articles were selected, consisting of one RCT, three cross-sectional studies, two cohort studies, two longitudinal/prospective studies, and one case-control study. A total of 5,545 participants were evaluated in the nine studies. Six non-randomized studies provided weak evidence of the relationship between vitamin D levels and diarrhea risk as there was no correlation between the two variables. The only RCT failed to demonstrate any beneficial role of vitamin D. Oral vitamin D

Topics: Cholecalciferol; Diarrhea; Dietary Supplements; Dysentery; Humans; Vitamin D; Vitamins

We conducted a follow up of the children in Mongolia whose mothers received one of the three doses of vitamin D (600, 2000, or 4000 IU daily) during pregnancy as part of the randomized, double-blind, clinical trial of vitamin D supplementation to determine their impact on child health to two years. In the parental trial, 119 pregnant women were assigned to 600 IU/day, 121 were assigned 2000 IU/day, and 120 were assigned 4000 IU/day starting at 12-16 weeks' gestation and continuing throughout pregnancy. At baseline, maternal serum 25(OH)D concentrations were similar across arms; 91 % were 50 nmol/l. As expected, there was a dose-response association between the amount of vitamin D consumed (600, 2000, or 4000 IU daily) and maternal 25(OH)D levels at the end of the intervention. Total 311 children of 311 mothers were followed for 2 years to evaluate health outcomes. We determined the child's health outcomes (rickets, respiratory disease [pneumonia, asthma], and diarrhea/vomiting) using a questionnaire and physical examination (3, 6, and 24 months of age). Low levels of mothers' serum 25(OH)D during pregnancy increased the risk of developing rickets, respiratory illness, and other diseases in children during the early childhood period. Rickets was diagnosed in 15.6 % of children of women who received 600 IU of vitamin D during pregnancy, which was higher than in other vitamin D groups. Children in the group whose mothers received low doses of vitamin D (600 IU/day) had a greater probability of developing respiratory diseases compared to the other groups: pneumonia was diagnosed in n = 36 (35.0 %) which was significantly higher than the group receiving vitamin D 4000 IU/day (n = 34 (31.5 %) p = 0.048). In the group whose pregnant mother consumed 600 IU/day of vitamin D, the risk of child pneumonia was ∼ 2 times higher than in the group who consumed 4000 IU/day (OR=1.99, 95 % CI: 1.01-3.90). The incidence of diarrhea and vomiting in children was 12.1 % lower in the 2000 IU/day group and 13.1 % lower in the 4000 IU/day group compared with the 600 IU/day group (p = 0.051). The offspring of pregnant women who regularly used vitamin D at doses above 600 IU/day had lower respiratory disease, rickets, and diarrheal risks at 2 years.

Topics: Child; Child Health; Child, Preschool; Cholecalciferol; Diarrhea; Dietary Supplements; Double-Blind Method; Female; Humans; Outcome Assessment, Health Care; Pneumonia; Pregnancy; Rickets; Vitamin D; Vitamin D Deficiency; Vitamins; Vomiting

This study aimed to evaluate whether vitamin D deficiency is associated with the severity of symptoms of irritable bowel syndrome (IBS) patients. Stress and gut inflammation can increase the serum level of corticotropin-releasing hormone (CRH) and interleukin-6 (IL-6), leading to a change in bowel movements. The aim of this study was to evaluate the anti-inflammatory and psychological effects of vitamin D3 supplementation on the symptom improvement of patients with a diarrhea-predominant form of IBS (IBS-D).. Eighty-eight IBS-D patients (age: 18-65 years) based on Rome IV criteria who suffered from vitamin D deficiency and/or insufficiency were enrolled in this randomized, placebo-controlled trial from February 2017 to May 2018 at Rasoul-e-Akram Hospital, Tehran, Iran. Participants were randomly divided into two groups. The intervention group received 50,000 IU vitamin D3 weekly and the control group received a placebo for 9 weeks. All patients received Mebeverine 135 mg twice a day besides supplementation. The IBS Severity Score System (IBS-SSS), serum 25(OH) vitamin D3, CRH, and IL-6 were measured before and after interventions.. Seventy-four patients completed the study. The severity of IBS symptoms (p < 0.01) and IL-6 (p = 0.02) decreased significantly in the intervention group as compared to the control group, but there was no significant difference in the serum level of CRH. Also, in the treatment group, IBS-SSS and IL-6 were significantly reduced at the end of the study from baseline (p < 0.01 and p < 0.03, respectively).. Our findings indicate that vitamin D3 supplementation can modulate the serum level of CRH and IL-6 and can improve symptoms in IBS-D patients. Vitamin D3 supplementation should be considered in IBS-D patients who suffer from vitamin D deficiency and/or insufficiency.. Ziele: Diese Studie untersucht den Zusammenhang zwischen Vitamin-D-Mangel und dem Schweregrad der Symptome von Patienten mit Reizdarmsyndrom (irritable bowel syndrome, IBS). Stress und Darmentzündung können erhöhte Serumkonzentrationen von Corticotropin-Releasing Hormone (CRH) und Interleukin-6 (IL-6) zur Folge haben, die zu Veränderungen des Stuhlverhaltens führen. Mit der vorliegenden Studie sollten die entzün­dungshemmenden und psychischen Effekte einer Vitamin-D3-Supplementierung auf die Symptomverbesse­rung von Patienten mit diarrhödominantem Reizdarmsyndrom (diarrhea-predominant form of IBS, IBS-D) beurteilt werden. Methoden: In diese randomisierte, placebokontrollierte Studie, die von Februar 2017 bis Mai 2018 am Rasoul-e-Akram Hospital in Teheran, Iran, durchgeführt wurde, wurden 88 Patienten mit IBS-D gemäß den Rom-IV-Kriterien (Alter: 18–65 Jahre) aufgenommen. Die Studienteilnehmer wurden randomisiert einer von zwei Gruppen zugeordnet. Die Interventionsgruppe erhielt wöchentlich über 9 Wochen 50’000 IU Vitamin D3, und die Kontrollgruppe erhielt ein Placebo. Alle Patienten erhielten neben der Supplementierung zweimal täglich Mebeverin 135 mg. Vor und nach der Intervention erfolgten eine Beurteilung der Krankheitsschwere gemäß IBS Severity Score System (IBS-SSS) sowie eine Bestimmung der Serumkonzentrationen von 25(OH)-Vitamin D3, CRH und IL-6. Ergebnisse: Vierundsiebzig Teilnehmer schlossen die Studienteilnahme ab. Der Schweregrad der IBS-Symptome (p < 0,01) und die IL-6-Serumkonzentration(p = 0,02) gingen in der Interventionsgruppe im Vergleich zur Kontrollgruppe signifikant zurück, während bei der CRH-Serumkonzentration kein signifikanter Unterschied zu beobachten war. Ferner zeigte sich in der Behandlungsgruppe bei Studienende ein signifikanter Rückgang des IBS-SSS und der IL-6-Serumkonzentration gegenüber Studienbeginn (p < 0,01 bzw. p < 0,03). Schlussfolgerung: Unsere Ergebnisse zeigen, dass eine Vitamin-D3-Supplementierung die Serumspiegel von CRH und IL-6 verändern und die Symptome von Patienten mit IBS-D verbessern kann. Bei Patienten mit IBS-D, die an einem Vitamin-D3-Mangel und/oder einer Vitamin-D3-Insuffizienz leiden, sollte eine Supplementierung mit Vitamin D3 in Betracht gezogen werden.

Topics: Adolescent; Adult; Aged; Biomarkers; Cholecalciferol; Corticotropin-Releasing Hormone; Diarrhea; Dietary Supplements; Double-Blind Method; Female; Humans; Interleukin-6; Irritable Bowel Syndrome; Male; Middle Aged; Vitamin D Deficiency; Young Adult

To investigate the effect of vitamin D3 supplementation on the incidence and risk for first and recurrent diarrheal illnesses among children in Kabul, Afghanistan.. This double-blind placebo-controlled trial randomized 3046 high-risk 1- to 11-month-old infants to receive 6 quarterly doses of oral vitamin D3 (cholecalciferol 100000 IU) or placebo in inner city Kabul. Data on diarrheal episodes (≥ 3 loose/liquid stools in 24 hours) was gathered through active and passive surveillance over 18 months of follow-up. Time to first diarrheal illness was analyzed by using Kaplan-Meier plots. Incidence rates and hazard ratios (HRs) were calculated by using recurrent event Poisson regression models.. No significant difference existed in survival time to first diarrheal illness (log rank P = .55). The incidences of diarrheal episodes were 3.43 (95% confidence interval [CI], 3.28-3.59) and 3.59 per child-year (95% CI, 3.44-3.76) in the placebo and intervention arms, respectively. Vitamin D3 supplementation was found to have no effect on the risk for recurrent diarrheal disease in either intention-to-treat (HR, 1.05; 95% CI, 0.98-1.17; P = .15) or per protocol (HR, 1.05; 95% CI, 0.98-1.12; P = .14) analyses. The lack of preventive benefit remained when the randomized population was stratified by age groups, nutritional status, and seasons.. Quarterly supplementation with vitamin D3 conferred no reduction on time to first illness or on the risk for recurrent diarrheal disease in this study. Similar supplementation to comparable populations is not recommended. Additional research in alternative settings may be helpful in elucidating the role of vitamin D3 supplementation for prevention of diarrheal diseases.

Topics: Afghanistan; Child, Preschool; Cholecalciferol; Diarrhea; Diarrhea, Infantile; Dietary Supplements; Double-Blind Method; Female; Follow-Up Studies; Humans; Infant; Male; Risk

The importance of sun exposure on human health is well recognized, and a recent trend in the avoidance of sun exposure has led to the risk of missing the beneficial effects such as vitamin D

Topics: Activities of Daily Living; Animals; Antibody Formation; Biomarkers; Cholecalciferol; Cytokines; Diarrhea; Disease Management; Disease Models, Animal; Disease Susceptibility; Dysbiosis; Environmental Exposure; Fecal Microbiota Transplantation; Female; Food Hypersensitivity; Gastrointestinal Microbiome; Humans; Intestinal Mucosa; Mice; Oxidative Stress; Phototherapy; Sunlight; T-Lymphocytes

Topics: Aged; Cholecalciferol; Clonazepam; Diarrhea; Esomeprazole; Female; Fluconazole; Humans; Nausea; Ondansetron; Piperacillin, Tazobactam Drug Combination; Syncope; Torsades de Pointes; Vancomycin

Topics: Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Cholecalciferol; Copper; Diarrhea; Diet; Digestion; Energy Metabolism; Feeding and Eating Disorders; Humans; Intestinal Mucosa; Intestine, Small; Parasite Egg Count; Phosphorus; Sheep; Sheep Diseases; Trichostrongyloidiasis

Topics: Animals; Animals, Newborn; Calcium; Cattle; Cattle Diseases; Chlortetracycline; Cholecalciferol; Diarrhea; Drug Combinations; gamma-Globulins; Phosphorus; Vitamin A; Vitamin E; Vitamins

Topics: Animals; Body Weight; Calcium; Cholecalciferol; Diarrhea